{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Unconfirmed Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Unconfirmed Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Stable/No Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Increasing Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Assessment Inadequate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions. No disease related symptoms. Normalization of markers and other normal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration.","groups":[{"description":"Patients received Gemcitabine 3,000 mg/m2 (IV on days 1 and 15 over 30 minutes) and Paclitaxel 150 mg/m2 (IV on days 1 and 15 over one hour). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response (CR) receive 4 additional courses beyond CR. Eligible patients who received any treatment were included in baseline measures.","id":"OG000","title":"Gemcitabine and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"All eligible patients with measurable disease who started treatment were included in response measures.","reportingStatus":"POSTED","timeFrame":"9 weeks - 3 years","title":"Response","type":"SECONDARY","unitOfMeasure":"participants"}